[Pubmed] Effects of rituximab on prognosis in myasthenia gravis: A single-center experience from Turkey
Posté : 11 oct. 2022 12:00
Ideggyogy Sz. 2022 Sep 30;75(9-10):351-359. doi: 10.18071/isz.75.0351.
ABSTRACT
BACKGROUND AND PURPOSE: Management of treatment-resistant patients with myasthenia gravis (MG) remains an important issue. This study aimed to evaluate the effects of rituximab (RTX) treatment on the prognosis of patients with acetylcholine receptor autoantibody-positive (AChR-Ab+), muscle-specific kinase autoantibody-positive (MuSK-Ab+), or seronegative or double seropositive MG.
METHODS: Nineteen patients treated with RTX between 2015 and 2020 were included in this study. Demographic and clinical characteristics, prognosis, and prognostic predictors of MG were evaluated retrospectively. The Myas-thenia Gravis Foundation of America Post-Inter-vention Status (MGFA-PIS) before RTX treatment (pre-RTX) and after RTX treatment (post-RTX) were recorded.
RESULTS: A total of 10 patients (52.6%) were AchR Ab+, 6 patients (31.6%) were MuSK Ab+, 1 patient (5.3%) was seronegative, and 2 patients (10.5%) were double seropositive. Steroid dose was pre-RTX 38.9±5.7 (25-45), it was post-RTX 10.5±10.3 (0-30) (p
Source: https://pubmed.ncbi.nlm.nih.gov/3621811 ... 6&v=2.17.8